Telomelysin® (OBP-301), the liver cancer new drug co-developed by Medigen Biotechnology Corp.(“Medigen”) and Oncolys BioPharma (“Oncolys”), enrolled first patient. Oncolys announced OBP-301 had enrolled first patient on July 28th, this is OBP-301 first sponsor-initiated Phase II clinical trial for the treatment of melanoma in the US. This trial will be carried out with 50 patients in five hospitals.
Reference:
Announcement from Oncolys BioPharma